Its subsidiary’s core product, TROP2 ADC Lukangsatuzumab, has been approved by the National Medical Products Administration for a third indication.
October 13, 2025
Source: drugdu
89
Kelun PharmaceuticalThe announcement stated that Kelun Biotech's controlled subsidiary, sac-TMT, an antibody-drug conjugate (ADC) targeting human trophoblast cell surface antigen 2 (TROP2), has been approved by the National Medical Products Administration for a third indication: the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation-positive disease who have progressed after treatment with an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). sac-TMT is the first and only ADC in the world to date to demonstrate a significant overall survival (OS) benefit compared to platinum-based doublet chemotherapy and has been approved for advanced NSCLC that has progressed after prior TKI therapy (2L).
https://finance.eastmoney.com/a/202510123531499855.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
